“Women with breast cancer who received first-line treatment with the nontaxane microtubule dynamics inhibitor eribulin mesylate were able to stay on treatment longer and had better clinical outcomes when they received dose modifications during their treatment, according to the results of a poster presented at the 32nd Annual Miami Breast Cancer Conference, held February 26–March 1 in Miami Beach, Florida.
“According to the researchers, led by Joyce O’Shaughnessy, MD, of the Texas Oncology–Baylor Charles A. Sammons Cancer Center, and US Oncology, Dallas, Texas, these results suggests that ‘the use of dose modification to manage adverse events may allow patients to achieve a longer duration of eribulin therapy, which in turn may result in improved outcomes.’
“Eribulin mesylate is currently approved for the treatment of metastatic breast cancer in patients who have previously received at least two prior lines of chemotherapy, including a taxane and an anthracycline. Recently though, two phase II studies looked at eribulin as a first-line treatment and showed that the drug had clinical activity with an acceptable toxicity profile.
“The first, Study 206, included 56 patients with HER2-negative breast cancer. The second, Study 208, included 52 patients with HER2-positive disease. All patients were assigned to eribulin 1.4 mg/m2 on days 1 and 8 of a 21-day cycle. Patients enrolled in Study 208 also received trastuzumab on day 1 of each cycle.”